Semaglutide vs. Tirzepatide: Which TeloMeds Option Fits Your Plan?

# Semaglutide vs. Tirzepatide: Which TeloMeds Option Fits Your Plan?

Updated August 11, 2026 · Reviewed for accuracy by the TeloMeds editorial team

Semaglutide and tirzepatide can both support substantial weight loss when prescribed with nutrition and activity changes. Tirzepatide produced greater average weight loss in the first direct trial, but that does not make it the right choice for everyone. Your medical history, side-effect tolerance, access, and clinician’s judgment still decide the better fit.

Quick takeaway: Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GIP and GLP-1 receptors. Both can reduce appetite and support long-term weight management, both can cause gastrointestinal side effects, and neither ensures a specific result. A clinician should compare the evidence with your health history rather than declare a universal winner.

TeloMeds options and pricing: TeloMeds offers physician-led semaglutide and tirzepatide programs for eligible patients. Introductory monthly pricing starts at $249 for semaglutide and $329 for tirzepatide. Introductory three-month packages start at $499 and $599, respectively. A licensed physician reviews your intake before any prescription is issued. Explore TeloMeds weight-loss care.

The shortest useful comparison

You can compare semaglutide and tirzepatide across six practical questions:

• Mechanism: Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors.
• Average trial result: Tirzepatide produced more average weight loss than semaglutide in a 72-week head-to-head trial in adults with obesity who did not have type 2 diabetes.
• Side effects: Both commonly cause gastrointestinal symptoms, especially while treatment is being increased under clinical supervision.
• Serious risks: Both labels carry important warnings and contraindications, including a boxed warning about thyroid C-cell tumors seen in rodents.
• Eligibility: Neither medication is appropriate for every patient. Other conditions, medications, pregnancy plans, and prior reactions can change the decision.
• TeloMeds price: Semaglutide starts at $249 for the introductory month; tirzepatide starts at $329. Longer prepaid plans are available for eligible patients.

Semaglutide and tirzepatide work through different pathways

Semaglutide copies the activity of glucagon-like peptide-1, or GLP-1, at its receptor. This pathway can affect appetite, food intake, and gastric emptying. In TeloMeds care, a licensed physician evaluates whether semaglutide is appropriate for your history and goals, then oversees the prescription and refill plan.

Tirzepatide activates receptors for both glucose-dependent insulinotropic polypeptide, or GIP, and GLP-1. That dual pathway is one reason tirzepatide may produce a different average response. TeloMeds offers tirzepatide as a physician-reviewed option for eligible patients rather than treating the higher trial average as an automatic recommendation.

The extra receptor target gives tirzepatide a different mechanism. It does not remove the need for screening, follow-up, or a sustainable plan around nutrition and activity.

What the head-to-head trial found

In SURMOUNT-5, tirzepatide produced a larger average reduction in body weight than semaglutide at 72 weeks. Researchers randomly assigned 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or semaglutide. Average weight change was 20.2% with tirzepatide and 13.7% with semaglutide. Average waist-circumference reduction was 18.4 cm and 13.0 cm, respectively (SURMOUNT-5, New England Journal of Medicine).

Those numbers need context:

• They are group averages, not promises for an individual patient.
• The trial compared maximum tolerated doses after dose escalation.
• Participants had obesity and did not have type 2 diabetes, so the result does not answer every clinical situation.
• The study was open-label and funded by Eli Lilly, tirzepatide’s manufacturer.
• Treatment response can differ with adherence, tolerability, health conditions, and the time a patient remains on therapy.

Separate placebo-controlled trials also showed that each medication can support meaningful weight loss. In STEP 1, semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% weight reduction at 68 weeks, compared with 2.4% for placebo (STEP 1, New England Journal of Medicine). In SURMOUNT-1, mean weight change at 72 weeks ranged from 15.0% to 20.9% across the studied tirzepatide doses, compared with 3.1% for placebo (SURMOUNT-1, New England Journal of Medicine).

You should not compare percentages from separate trials as if researchers ran them under identical conditions. The head-to-head trial offers the cleaner comparison, while the individual trials show the evidence base behind each option.

Side effects overlap, but the decision is still personal

Gastrointestinal symptoms are the most common side effects with both medications. Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion appear in the prescribing information. In SURMOUNT-5, gastrointestinal events were the most common adverse events in both groups; most were mild to moderate and occurred during dose escalation.

A lower average trial result may still be the better trade-off for a patient who tolerates one medicine and not the other. Side-effect management should stay with the prescribing clinician. It may involve reviewing symptoms, hydration, meal patterns, interacting medications, and whether treatment remains appropriate. This article does not provide a dosing or titration plan.

Contact your clinician if symptoms are persistent, worsening, or make it difficult to eat or drink. Seek urgent medical care for signs of a serious allergic reaction, such as trouble breathing or swelling of the face or throat. Severe and persistent abdominal pain can require prompt evaluation, including for pancreatitis.

The important safety questions come before the “better” medication

Both medications require screening for contraindications, warnings, and medication interactions. Current prescribing information includes a boxed warning about thyroid C-cell tumors observed in rodents. These treatments are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

A clinician may also review:

• Prior pancreatitis, gallbladder disease, or severe gastrointestinal problems
• Kidney risk, especially if vomiting or diarrhea could cause dehydration
• Diabetes medications that can raise the risk of low blood sugar
• A history of serious hypersensitivity to the medication or its ingredients
• Pregnancy, plans to become pregnant, and contraceptive considerations
• Other prescriptions, supplements, and prior weight-management treatments

The two labels are not interchangeable. Tirzepatide’s effect on gastric emptying creates specific oral-medication considerations, including guidance about oral hormonal contraceptives during certain treatment periods. Semaglutide has product-specific warnings and formulation instructions of its own. Your clinician should use the label for the exact product under consideration.

How clinical guidelines frame the choice

Obesity guidelines treat medication as one part of long-term care, not a stand-alone shortcut. The American Gastroenterological Association recommends adding pharmacotherapy to lifestyle intervention for eligible adults who have had an inadequate response to lifestyle measures alone. Its guideline emphasizes long-term management and patient-specific selection rather than naming one medication as best for everyone (AGA clinical practice guideline).

That approach gives you a more useful decision standard. The best-fit option is the one a clinician expects you can use safely, tolerate, access, and continue as part of a durable plan. The medication with the higher trial average does not help if it is contraindicated, poorly tolerated, inaccessible, or stopped without a follow-up strategy.

What semaglutide and tirzepatide cost through TeloMeds

TeloMeds publishes the price of the treatment path instead of sending you to compare retail brand coupons:

• Semaglutide: $249 introductory monthly plan or $499 introductory three-month plan.
• Tirzepatide: $329 introductory monthly plan or $599 introductory three-month plan.

Standard ongoing monthly pricing depends on the medication and prescribed level. Current TeloMeds list pricing is $269 for ongoing monthly semaglutide plans and $399 for ongoing monthly tirzepatide plans. Six- and twelve-month options are also available. Pricing can change, and a prescription is issued only when a licensed physician determines that treatment is appropriate.

The practical comparison is therefore not only “which molecule had the higher trial average?” It is which physician-reviewed plan fits your health history, tolerance, goals, and budget well enough to continue.

A practical decision checklist for your clinician visit

Bring a complete medication list and be ready to discuss:

1. Your weight history and what you have already tried
2. Weight-related conditions and your current treatment plan
3. Gastrointestinal, gallbladder, pancreatic, kidney, endocrine, and eye history
4. Personal or family history of medullary thyroid carcinoma or MEN2
5. Pregnancy plans and contraception, when relevant
6. Side effects or allergic reactions from prior medications
7. Insurance coverage and a realistic monthly budget
8. The follow-up plan if the first option is not tolerated or accessible

You do not need to choose a “winner” before that visit. You need enough information to ask better questions and understand the trade-offs.

Compare both options with one TeloMeds intake

You do not need to diagnose yourself or choose the medication from a headline. Start with one online medical intake. A licensed TeloMeds physician reviews your history, current medications, prior weight-loss attempts, and goals, then decides whether semaglutide, tirzepatide, or another path is appropriate.

If prescribed, the medication is fulfilled through a partner pharmacy and shipped as part of your treatment plan. Compare TeloMeds weight-loss options and start your intake. You can also review the medication-safety information and TeloMeds FAQs before you begin. Individual results vary.

Frequently asked questions

Is tirzepatide better than semaglutide for weight loss?

Tirzepatide produced greater average weight loss in the 72-week SURMOUNT-5 head-to-head trial. That finding does not make tirzepatide the right medication for every patient. Contraindications, side effects, health history, access, and clinician judgment can make semaglutide or another approach a better fit.

Is tirzepatide the same as a GLP-1 medication?

Tirzepatide acts on the GLP-1 receptor and the GIP receptor, so clinicians may discuss it alongside GLP-1 medicines even though its mechanism has two receptor targets. Semaglutide acts on the GLP-1 receptor. Both are incretin-based medicines used in weight-management care.

Do semaglutide and tirzepatide have the same side effects?

They share common gastrointestinal side effects, including nausea, diarrhea, vomiting, and constipation. Their labels are not identical, and individual tolerance varies. A prescribing clinician should review the exact product, your other medications, and any symptoms that develop during treatment.

Can you switch from semaglutide to tirzepatide?

A clinician may consider a switch when the first medication is not effective enough, is not tolerated, or becomes inaccessible. Switching requires a product-specific plan. Do not overlap, combine, or change these medications without the prescriber’s instructions.

Which medication costs less?

At TeloMeds, introductory monthly semaglutide pricing starts at $249 and tirzepatide pricing starts at $329. Introductory three-month plans start at $499 and $599, respectively. Ongoing list prices depend on the medication and prescribed level; current standard monthly pricing is $269 for semaglutide and $399 for tirzepatide.

How quickly should you expect results?

Clinical trials report average changes over many months, not a fixed week-by-week schedule. Your response can depend on the treatment you tolerate, the time you remain on it, and your broader care plan. Your clinician should set expectations and review progress at appropriate follow-up visits.

References

• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. 2025.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. 2021.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. 2022.
• Grunvald E, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. 2022.

This article is for general medical information and does not diagnose a condition, recommend a medication, or replace care from a licensed clinician. Prescription treatment requires an individual medical evaluation. Seek urgent care for severe or rapidly worsening symptoms.